Deoxyribonuclease I (DNase I), an enzyme that can break down the nucleic acid backbone of NETs is a promising drug candidate for their clearance.[10] DNase I inhalation therapy has been approved by the US Food and Drug Administration in cystic fibrosis.[11] However, the current inhalation delivery is not suitable for ARDS patients, who typically require mechanical ventilation support. The gene discussed is DNASE1; the disease is acute respiratory distress syndrome.